FDA
-
-
-
-
-
-
-
Passage Bio reports interim trial data, initiates strategic review
-
-
-
-
-
-
-
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
-
-
-
-
-
-
-
Passage Bio (PASG) Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis
-
-
-
-
-
-
-
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
-
-
-
-
-
-
-
Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy
-
-
-
-
-
-
-
Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
-
-
-
-
-
-
-
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
-
325,028 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

